What changed
$SNPS — AVOID 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ2 FY2026 (ends Apr) | reported May 27 | Rev $2.3B | EPS $3.35 vs $3.16 🟢 | Margin 39.5%
💡 Consensus expects ~15% earnings growth and sustained high multiples; the modest beat and potential macro headwinds could lead to growth disappointment and multiple compression.
🏢 Business Quality: 8 — dominant EDA software provider with sticky customers, high margins, and essential technology, but faces high R&D costs and cyclical semiconductor exposure./10
📊 Valuation: rich — trailing P/E 33.9x, EV/OpInc ~105x, premium to sector peers; fair value range $340-410 based on 25-30x normalized earnings.
🔮 Catalyst: next quarterly earnings release
⚖️ Avoid SNPS at current levels; the risk/reward is unfavorable with limited upside and significant downside if growth expectations fail to materialize.